ArticleInternational journal of impotence research2026
Prevalence and patterns of sexual dysfunctions among male cancer survivors: real-world evidence from a tertiary andrology centre.
Article in International journal of impotence research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male cancer survivors may develop sexual dysfunction (SD) even many years after recovery from cancer. We aimed to evaluate the prevalence of and the clinical characteristics of cancer survivors among men seeking medical help for SD (any) in the real-life setting of an andrological tertiary-referral centre. Complete data from 2712 men consecutively assessed for new-onset SD between 2005 and 2022 were analysed. All patients were assessed with a comprehensive sexual and medical history, including history of any non-metastatic cancer (i.e., urological cancers, non-urological solid cancers, haematological malignancies). All patients were invited to complete the International Index of Erectile Function (IIEF). The IIEF-Erectile function (IIEF-EF) domain was categorized according to Cappelleri's criteria. Of all, 239 (8.8%) patients primarily assessed for SD reported a history of non-metastatic cancers. Among cancer survivors, the most frequent complaint was ED (76.2%), followed by Peyronie's disease (PD) (13.8%), low sexual desire/interest (LSD/I) (13.4%), premature ejaculation (PE) (6.7%), and delayed ejaculation (DE) (2.1%), respectively. Of all, prostate cancer (PCa) and colorectal cancer (CRC) survivors accounted for 36.0% and 10.5% of all cancer survivors, respectively. Men with a history of PCa and/or CRC more frequently complained of ED [104(93.7) vs. 78(60.9) men; p = 0.002] and had lower median (IQR) IIEF-EF scores [7(3-10.5) vs. 11(7-21); (p < 0.001)], compared to patients with a history of other malignancies, whom conversely reported higher rates of PE [4(3.6%) vs. 12(9.4%) men; p = 0.04] and PD [10(9.0%) vs. 23(18.0%) men; p = 0.009]. Almost one out of ten men seeking first medical help for SD in a tertiary-referral andrology centre are cancer survivors. Following the improvement of survivorship rates in male patients, an andrological assessment should always be included over the follow-up of cancer survivors.
Identifiers
41491411What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.